Capital Research Global Investors
ALLO icon

Capital Research Global Investors’s Allogene Therapeutics ALLO Stock Holding History

Capital Research Global Investors’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-5,404,294
Closed -$139M – 442
2021
Q3 		$139M Sell
5,404,294
-6
-0% -$142 0.03% 281
2021
Q2 		$141M Sell
5,404,300
-7,259,713
-57% -$207M 0.03% 272
2021
Q1 		$447M Buy
12,664,013
+23,675
+0.2% +$799K 0.11% 169
2020
Q4 		$319M Buy
12,640,338
+22,346
+0.2% +$728K 0.08% 195
2020
Q3 		$476M Buy
12,617,992
+609,223
+5% +$23M 0.14% 141
2020
Q2 		$514M Buy
12,008,769
+3,036,198
+34% +$110M 0.16% 132
2020
Q1 		$174M Buy
8,972,571
+2,429,893
+37% +$57.9M 0.07% 195
2019
Q4 		$170M Buy
6,542,678
+1,268,228
+24% +$34.9M 0.05% 223
2019
Q3 		$144M Buy
5,274,450
+24
+0% +$684 0.05% 238
2019
Q2 		$142M Buy
5,274,426
+1,923,894
+57% +$53.6M 0.05% 239
2019
Q1 		$95.7M Buy
3,350,532
+843,344
+34% +$24.5M 0.03% 266
2018
Q4 		$62.6M Buy
+2,507,188
New +$66.6M 0.02% 294

Other funds holding ALLO

TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital Research Global Investors's ALLO Position: Q4 2021 in Review

Capital Research Global Investors sold out of Allogene Therapeutics (ALLO) in Q4 2021, closing a stake of 5,404,294 shares — an estimated $139M sold.

Capital Research Global Investors first reported a position in ALLO in Q4 2018 and held it in 12 quarters. The position peaked at $514M in Q2 2020. 177 funds tracked by Wall St. Rank hold ALLO as of Q4 2021.

  • Capital Research Global Investors reported no remaining Allogene Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Capital Research Global Investors sold 5,404,294 Allogene Therapeutics shares in Q4 2021, an estimated $139M.
  • Capital Research Global Investors first reported a position in Allogene Therapeutics in Q4 2018 and held it in 12 quarters.
  • Capital Research Global Investors's Allogene Therapeutics position peaked at $514M in Q2 2020.
  • 177 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2021.

Based on Capital Research Global Investors's 13F filing for Q4 2021, filed 14 Feb 2022.